JP2024540142A5 - - Google Patents

Info

Publication number
JP2024540142A5
JP2024540142A5 JP2024525528A JP2024525528A JP2024540142A5 JP 2024540142 A5 JP2024540142 A5 JP 2024540142A5 JP 2024525528 A JP2024525528 A JP 2024525528A JP 2024525528 A JP2024525528 A JP 2024525528A JP 2024540142 A5 JP2024540142 A5 JP 2024540142A5
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical composition
administration period
composition according
during
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2024525528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540142A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/048249 external-priority patent/WO2023076615A1/en
Publication of JP2024540142A publication Critical patent/JP2024540142A/ja
Publication of JP2024540142A5 publication Critical patent/JP2024540142A5/ja
Withdrawn legal-status Critical Current

Links

JP2024525528A 2021-10-29 2022-10-28 慢性副鼻腔炎を治療するためのある特定のn-(1-シアノ-2-フェニルエチル)-1,4-オキサゼパン-2-カルボキサミド Withdrawn JP2024540142A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163273540P 2021-10-29 2021-10-29
US63/273,540 2021-10-29
PCT/US2022/048249 WO2023076615A1 (en) 2021-10-29 2022-10-28 Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis

Publications (2)

Publication Number Publication Date
JP2024540142A JP2024540142A (ja) 2024-10-31
JP2024540142A5 true JP2024540142A5 (cg-RX-API-DMAC7.html) 2025-11-06

Family

ID=86158626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525528A Withdrawn JP2024540142A (ja) 2021-10-29 2022-10-28 慢性副鼻腔炎を治療するためのある特定のn-(1-シアノ-2-フェニルエチル)-1,4-オキサゼパン-2-カルボキサミド

Country Status (9)

Country Link
US (1) US20250049813A1 (cg-RX-API-DMAC7.html)
EP (1) EP4423071A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024540142A (cg-RX-API-DMAC7.html)
KR (1) KR20240099179A (cg-RX-API-DMAC7.html)
CN (1) CN118159525A (cg-RX-API-DMAC7.html)
AU (1) AU2022376535A1 (cg-RX-API-DMAC7.html)
CA (1) CA3236069A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024005126A (cg-RX-API-DMAC7.html)
WO (1) WO2023076615A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (cg-RX-API-DMAC7.html) 2014-01-24 2018-02-24
PT3758708T (pt) 2018-03-01 2025-02-13 Astrazeneca Ab Composições farmacêuticas compreendendo (2s)-{(1,s)-1-ciano-2-[4-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida
CA3106269A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
JP2026503035A (ja) 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性dpp1阻害剤及びその用途
WO2025162472A1 (en) 2024-01-31 2025-08-07 Insmed Incorporated Linear dipeptidyl peptidase 1 inhibitors and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (cg-RX-API-DMAC7.html) * 2014-01-24 2018-02-24
PT3758708T (pt) * 2018-03-01 2025-02-13 Astrazeneca Ab Composições farmacêuticas compreendendo (2s)-{(1,s)-1-ciano-2-[4-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida
WO2020023962A1 (en) * 2018-07-27 2020-01-30 Massachusetts Eye And Ear Infirmary Inhibition of cystatins for the treatment of chronic rhinosinusitis

Similar Documents

Publication Publication Date Title
JP2024009951A5 (cg-RX-API-DMAC7.html)
JP2015526458A5 (cg-RX-API-DMAC7.html)
Carlos Fabue et al. Dental management of patients with endocrine disorders
US20120034307A1 (en) Aqueous gel formulation and method for inducing topical anesthesia
JP2022516945A5 (cg-RX-API-DMAC7.html)
RU2011139643A (ru) Способ лечения неалкогольного стеатогепатита повышенными дозами урсодезоксихолевой кислоты
JP2023540485A5 (cg-RX-API-DMAC7.html)
JP2025508359A5 (cg-RX-API-DMAC7.html)
JP2023525571A5 (cg-RX-API-DMAC7.html)
JP2021525729A5 (cg-RX-API-DMAC7.html)
RU2009135078A (ru) Новые способы
JP2017132791A (ja) 組み合わせ組成物
JP2024516826A5 (cg-RX-API-DMAC7.html)
JP2019509985A5 (cg-RX-API-DMAC7.html)
JP2024527023A5 (cg-RX-API-DMAC7.html)
JP2024531188A5 (cg-RX-API-DMAC7.html)
JP2024507367A5 (cg-RX-API-DMAC7.html)
JP2023522415A5 (cg-RX-API-DMAC7.html)
JP2023553253A5 (cg-RX-API-DMAC7.html)
JP2023548429A5 (cg-RX-API-DMAC7.html)
Shin et al. Dental treatment in patients with severe gag reflex using propofol-remifentanil intravenous sedation
JP2023538419A5 (cg-RX-API-DMAC7.html)
JP2023543439A5 (cg-RX-API-DMAC7.html)
Floriano et al. Dental management in palliative care of a patient with advanced oral cancer: A case report
JP2024518804A5 (cg-RX-API-DMAC7.html)